Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY19 results · Jan–Mar 2019
Neuland Laboratories reported revenue from operations of ₹0.00 crore and net profit of ₹0.00 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.00 | — | — | — | — |
| Other income | 0.00 | — | — | — | — |
| Total income | 0.00 | — | — | — | — |
| Profit before tax | 0.00 | — | — | — | — |
| Net profit for the period | 0.00 | — | — | — | — |
| EPS, basic (₹) | 0.00 | — | — | — | — |
| Net margin (%) | — | — | — |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.66 | — | — | 171.47 | +0.7% |
| Other income | 1.33 | — | — | 0.41 | +229.2% |
| Total income | 174.00 | — | — | 171.87 | +1.2% |
| Profit before tax | 8.09 | — | — | 5.90 | +37.2% |
| Net profit for the period | 6.73 | — | — | 4.60 | +46.3% |
| EPS, basic (₹) | 5.25 | — | — | 3.59 | +46.2% |
| Net margin (%) | 3.9 | — | 2.7 |
Consolidated
- Filed with BSE
- 17 May 2019, 11:31 IST
- Board meeting
- 16 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2019, 11:27 IST
- Board meeting
- 16 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE